Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development for a complex, multifaceted, poorly understood disease; regulatory hurdles; a…
Crohn’s disease (CD) is a chronic debilitating illness with limited effective treatment options, especially for patients with moderate to severe disease. Treatment options for CD include…
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current…
As of 2016, over 2 million people across the EU5 countries have a diagnosis of schizophrenia. Many of the oral atypical antipsychotic therapies used to treat the symptoms of schizophrenia are…
Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening…
The approval of the first oncolytic viral therapy, Imlygic, in the United States and EU5 in 2015 and 2016, respectively, marks a significant milestone for cancer vaccines and viral therapies,…
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral (ARV) agents, particularly the latest single-tablet regimens (STRs), which offer improved safety and…
The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…
In late age-related macular degeneration (AMD), vision deficits are noticeable, are often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (…
The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary…
In China, multiple myeloma treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and thalidomide—while the treatment for…
Nearly 23 million people across the EU5 suffer from major depressive disorder. Generic availability of a growing number of therapies has improved patient access to antidepressants and loosened…
Ulcerative colitis (UC) affects approximately 1.75 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild and moderate patients; however,…